Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma

BACKGROUND: Glycogen synthase kinase (GSK)-3β has emerged as an appealing therapeutic target for glioblastoma (GBM). Here, we investigated the therapeutic effect of the current approved drugs against GBM via inhibition of GSK3β activity both, in experimental setting and in a clinical study for recur...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuta, Takuya, Sabit, Hemragul, Dong, Yu, Miyashita, Katsuyoshi, Kinoshita, Masashi, Uchiyama, Naoyuki, Hayashi, Yasuhiko, Hayashi, Yutaka, Minamoto, Toshinari, Nakada, Mitsutoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410264/
https://www.ncbi.nlm.nih.gov/pubmed/28423558
http://dx.doi.org/10.18632/oncotarget.15206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410264/
https://www.ncbi.nlm.nih.gov/pubmed/28423558
http://dx.doi.org/10.18632/oncotarget.15206

Ejemplares similares